Replies to post #97373 on Biotech Values

[DewDiligence]

AGN is trying to cash in on the aesthetic medical field, and they are not doing that well. Botox is being successfully challenged by Dysport…

That depends on how you define successfully. Botox’s market share in the US is 86% in cosmetic procedures and close to 100% in medical procedures. Worldwide, for all kinds of procedures, Botox’s market share is about 85%.

In the next year or so other competitors will enter the market.

It will be a little longer than that. JNJ’s BLA submission for PurTox is expected in 4Q10, so the US launch is unlikely to occur before late 2011 or early 2012.

[DewDiligence]

MRX insiders have been very heavy sellers lately—perhaps the prospects for Dysport are faltering. Here are the details…

Jonah Shacknai, CEO, sold $11M worth:
http://sec.gov/Archives/edgar/data/859368/000124636010003037/xslF345X03/form.xml

Mark Prygocki, President, sold $3M worth:
http://sec.gov/Archives/edgar/data/859368/000124636010003038/xslF345X03/form.xml

Vincent Ippolito, EVP Sales, sold $350K worth:
http://sec.gov/Archives/edgar/data/859368/000124636010003035/xslF345X03/form.xml

Richard Peterson, CFO, sold $200K worth:
http://sec.gov/Archives/edgar/data/859368/000124636010003036/xslF345X03/form.xml

[DewDiligence]

I wonder if this botulinum-toxin patent will stand up to scrutiny:

http://finance.yahoo.com/news/Microdroplet-BOTOX-Technology-bw-981641444.html?x=0&.v=1

Microdroplet™ botulinum toxin (BOTOX®, Dysport®, Xeomin®) is a precise method of elevating the eyebrow position and softening overactive muscles to enhance one’s facial appearance. Whereas standard botulinum toxin treatments involve injecting larger amounts of botulinum toxin in relatively few places, Microdroplet™ botulinum toxin relies on tiny injection volumes of botulinum toxin dissolved in microdroplets. This controlled placement avoids the most common BOTOX® side effects of the “frozen forehead” or “bat face.”